Cost Analysis of New Antibiotics to Treat Multidrug-Resistant Bacterial Infections: Mind the Gap

INTRODUCTION: Guidelines for treatment of multidrug-resistant (MDR) bacteria rely on newly approved antibiotics, with limited evidence of their effectiveness for treating these infections. Data regarding cost of such an approach are lacking. We aimed to evaluate estimated cost of using newly approve...

Descripción completa

Detalles Bibliográficos
Autores principales: Yahav, Dafna, Shepshelovich, Daniel, Tau, Noam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955006/
https://www.ncbi.nlm.nih.gov/pubmed/33594649
http://dx.doi.org/10.1007/s40121-021-00412-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955006/
https://www.ncbi.nlm.nih.gov/pubmed/33594649
http://dx.doi.org/10.1007/s40121-021-00412-y

Ejemplares similares